chronic
viral
hepat
c
hcv
character
progress
fibrosi
ultim
lead
format
cirrhosi
manag
chronic
hepat
depend
degre
liver
fibrosi
thu
assess
degre
liver
fibrosi
import
choos
therapeut
strategi
determin
prognosi
liver
biopsi
gold
standard
method
evalu
degre
liver
fibrosi
howev
invas
natur
liver
biopsi
make
impract
especi
patient
requir
followup
therefor
mani
report
demonstr
noninvas
examin
method
assess
degre
fibrosi
chronic
liver
diseas
may
altern
liver
biopsi
new
serum
biomark
biomark
panel
transient
elastographi
pentraxin
essenti
compon
humor
arm
innat
immun
involv
resist
microorgan
inflamm
well
establish
key
activ
inflammatori
repar
respons
tissu
injuri
proinflammatori
cytokin
damag
tissuederiv
signal
microbi
molecul
induc
product
differ
cell
type
includ
vascular
endotheli
cell
mesenchym
cell
fibroblast
well
cell
innat
immun
monocyt
granulocyt
neutrophil
store
secondari
granul
upon
appropri
stimul
promptli
releas
simplist
view
play
crucial
role
inflamm
activ
complement
cascad
inhibit
pselectinmedi
neutrophil
extravas
sinc
acutephas
protein
rapidli
produc
vascular
tissu
well
cell
innat
immun
respons
inflamm
rapid
reliabl
marker
primari
local
activ
innat
immun
inflamm
sever
disord
includ
acut
kidney
injuri
sever
acut
respiratori
syndrom
lpsinduc
lung
injuri
atherosclerosi
acut
myocardi
infarct
detail
see
review
recent
doni
et
al
agreement
previou
report
shown
nonredund
protect
role
regul
tissu
repair
remodel
variou
murin
model
tissu
damag
includ
skinwound
heal
chemic
induc
steril
liver
lung
injuri
arteri
thrombosi
defici
associ
increas
clot
well
fibrin
collagen
depositionpersist
epitheli
hyperplasia
defect
matur
tissu
format
heal
phenotyp
attribut
lack
facilit
plasminmedi
fibrinolysi
tissu
remodel
cell
prerequisit
appropri
tissu
repair
respect
fibrin
provision
extracellular
matrix
protein
deposit
tissu
injuri
subsequ
time
degrad
essenti
tissu
repair
mention
particip
wound
heal
respons
differ
organ
includ
liver
experi
cell
show
mainli
express
neutrophil
healthi
liver
injuri
mainli
express
hepat
stellat
cell
hsc
main
cell
type
respons
repar
respons
tissu
injuri
liver
fibrosi
differenti
express
healthi
injur
liver
togeth
data
show
drive
hsc
activ
suggest
respons
injuri
releas
neutrophil
may
promot
hsc
activ
howev
chronic
liver
diseas
activ
hsc
would
becom
main
cell
type
produc
may
enhanc
repar
respons
liver
injuri
exert
protect
immun
modulatori
effect
light
observ
clinic
studi
need
elucid
precis
role
liver
fibrosi
close
associ
level
diseas
progress
stage
liver
fibrosi
patient
nonalcohol
fatti
liver
diseas
alcohol
hepat
shown
one
studi
concern
polymorph
analyz
abil
serum
level
predict
liver
fibrosi
hcv
patient
author
decid
includ
signific
fibrosi
group
studi
ensur
homogen
phenotyp
knowledg
studi
first
one
examin
diagnost
accuraci
characterist
serum
level
hcv
patient
signific
advanc
fibrosi
hypothes
measur
could
provid
altern
exist
noninvas
serum
marker
assess
diseas
stage
crosssect
studi
hcv
patient
primari
aim
evalu
identifi
hcv
patient
urgent
need
antivir
treatment
metavir
fibrosi
whose
treatment
could
defer
metavir
fibrosi
secondari
aim
compar
diagnost
valu
valid
fibrosi
marker
includ
serum
marker
hyaluron
acid
ha
transform
growth
aspart
aminotransferas
ast
platelet
index
apri
score
ggt
platelet
ratio
gpr
liver
stiff
measur
transient
elastographi
studi
found
provid
clinic
relev
diagnost
accuraci
singl
marker
liver
fibrosi
studi
cohort
consist
adult
includ
healthi
volunt
patient
chronic
hepat
c
admit
depart
infecti
diseas
hepatolog
octob
decemb
diagnosi
chronic
hepat
c
infect
base
persist
increas
alanin
aminotransferas
valu
antihcv
hcvrna
posit
liver
histolog
featur
hcv
inflamm
confirm
measur
hcvab
hcvrna
serum
use
eia
method
rt
pcr
coba
amplicor
roch
method
respect
patient
dualli
infect
hcv
hbv
patient
fatti
liver
might
influenc
valu
exclud
patient
known
substanc
alcohol
andor
intraven
drug
abus
well
hiv
human
immunodefici
viru
autoimmun
congenit
metabol
liver
condit
malign
treat
immunosuppress
exclud
studi
well
none
patient
receiv
antivir
therapi
prior
inclus
purpos
examin
fulli
explain
inform
consent
obtain
particip
studi
protocol
approv
ethic
committe
bioethic
committe
wroclaw
medic
univers
carri
accord
declar
helsinki
revis
liver
biopsi
perform
part
workup
assess
sever
inflamm
fibrosi
stain
biopsi
examin
one
expert
pathologist
blind
patient
clinic
characterist
score
accord
metavir
score
system
degre
fibrosi
fibrosi
portal
fibrosi
alon
portal
fibrosi
rare
septa
portal
fibrosi
mani
septa
cirrhosi
degre
necroinflammatori
activ
mild
activ
mark
activ
presenc
stage
refer
signific
fibrosi
presenc
stage
refer
advanc
fibrosi
patient
classifi
metavir
compens
diseas
sampl
peripher
venou
blood
fast
patient
chronic
hepat
c
taken
day
liver
biopsi
procedur
examin
carri
blood
allow
clot
min
centrifug
min
room
temperatur
serum
separ
aliquot
tube
storag
tube
frozen
store
order
use
analysi
differ
paramet
concentr
alanin
transaminas
alt
aspart
transaminas
ast
ggt
total
bilirubin
serum
albumin
platelet
leukocyt
cholesterol
hdlcholesterol
triglycerid
hyaluron
acid
intern
normal
ratio
inr
measur
use
standard
clinic
method
model
endstag
liver
diseas
meld
score
calcul
use
bilirubin
creatinin
inr
aspart
aminotransferas
ast
platelet
index
apri
score
gpr
ratio
calcul
base
follow
formula
apri
index
ast
iul
upper
normal
limit
x
score
age
year
x
ast
iul
platelet
x
alt
iul
gpr
ratio
ggt
iul
platelet
ggt
level
determin
use
elisa
method
cloudclon
corp
houston
usa
follow
instruct
manual
provid
manufactur
elisa
plate
reader
model
go
micropl
reader
thermo
finland
use
measur
color
intens
accord
instruct
manual
provid
manufactur
level
sampl
determin
control
sampl
serum
standard
concentr
rang
ngml
includ
run
minimum
detect
dose
typic
less
ngml
serum
level
ha
measur
use
latex
agglutin
turbidimetri
echelon
bioscienc
salt
lake
citi
usa
concentr
measur
use
immunoenzymat
method
diaclon
sa
besancon
cedex
franc
transient
elastographi
echosen
pari
perform
skill
oper
assess
lsm
liver
stiff
measur
valu
lsm
transient
elastographi
express
kilopasc
kpa
evalu
relat
interquartil
rang
iqr
success
rate
measur
iqr
less
mean
liver
stiff
success
rate
valid
measur
indic
success
measur
accord
tsochatzi
et
al
liver
stiff
cutoff
present
scale
accord
given
rang
kpa
stage
chronic
hepat
c
patient
respect
continu
variabl
express
median
interquartil
rang
iqr
mean
standard
deviat
categor
variabl
number
percentag
perform
oneway
analysi
varianc
anova
evalu
whether
use
judg
metavir
fibrosi
score
afterward
examin
correl
liver
function
paramet
convent
fibrosi
marker
use
spearman
rank
correl
logist
regress
analys
p
valu
independ
variabl
determin
wald
chisquar
valu
wald
calcul
squar
ratio
regress
coeffici
divid
standard
error
diagnost
valu
predict
signific
advanc
fibrosi
cirrhosi
assess
calcul
area
receiv
oper
characterist
roc
curv
roc
curv
gener
plot
sensit
specif
area
curv
auc
confid
interv
ci
calcul
accord
delong
empir
nonparametr
method
perform
make
pairwis
comparison
roc
curv
base
roc
analysi
optimum
cutoff
point
establish
select
valu
provid
greatest
sum
sensit
specif
ie
point
closest
upper
left
point
roc
plot
optimum
cutoff
point
provid
roc
analysi
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
calcul
use
standard
formula
statist
signific
defin
p
statist
analys
perform
use
statistica
version
r
version
basic
clinic
biochem
data
hcv
patient
healthi
control
present
tabl
case
hcv
patient
median
age
year
male
predomin
median
age
control
group
year
femal
predomin
metavir
fibrosi
score
hcv
patient
patient
patient
patient
patient
patient
median
level
ngml
iqr
ngml
hcv
patient
underw
test
fibrosi
stage
lsm
case
lsm
case
lsm
case
far
healthi
control
concern
median
level
ngml
iqr
ngml
patient
chronic
hepat
c
valu
fibrosi
marker
hyaluron
acid
ha
median
ngml
iqr
ngml
transform
growth
median
ngml
iqr
ngml
apri
index
median
iqr
score
median
iqr
astalt
ratio
median
iqr
gpr
ratio
median
iqr
tabl
increas
increas
score
inflammatori
activ
figur
correl
metavir
inflamm
score
rho
p
hcv
patient
significantli
correl
histolog
stage
liver
fibrosi
rho
p
level
significantli
higher
patient
signific
fibrosi
compar
p
figur
b
also
significantli
higher
patient
advanc
fibrosi
compar
p
figur
c
use
order
logist
regress
analysi
metavir
fibrosi
score
depend
variabl
ten
biochem
paramet
explanatori
variabl
univari
analys
natur
logarithm
serum
level
provid
signific
coeffici
wald
p
wald
p
respect
tabl
sinc
relat
histolog
stage
liver
fibrosi
hcv
patient
investig
whether
correl
valid
fibrosi
marker
includ
direct
serum
marker
hyaluron
acid
ha
transform
growth
indirect
marker
aspart
aminotransferas
ast
platelet
index
apri
index
score
gammaglutamyltranspeptidas
platelet
ratio
gpr
ratio
serum
level
significantli
correl
ha
figur
figur
b
p
also
signific
correl
level
indirect
serum
marker
liver
fibrosi
includ
apri
index
figur
c
score
figur
gpr
ratio
figur
e
p
addit
use
spearman
rank
correl
analysi
posit
correl
lsm
level
rho
p
observ
figur
f
result
strongli
suggest
signific
associ
histolog
sever
liver
fibrosi
area
roc
curv
use
evalu
diagnost
valu
detect
signific
advanc
fibrosi
cirrhosi
figur
tabl
best
marker
auc
detect
figur
auc
detect
auc
detect
cirrhosi
figur
c
optim
cutoff
valu
predict
fibrosi
stage
cirrhosi
ngml
respect
tabl
roc
curv
hyaluron
acid
ha
apri
index
score
gpr
ratio
lsm
valu
predict
signific
fibrosi
shown
figur
analyz
diagnost
accuraci
level
predict
fibrosi
stage
roc
area
roc
p
figur
optim
cutoff
point
predict
ngml
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
respect
tabl
use
delong
method
pairwis
comparison
roc
curv
perform
estim
signific
fibrosi
auc
level
auc
higher
gpr
ratio
auc
p
differ
signific
compar
score
auc
p
apri
index
auc
p
ha
auc
p
compar
lsm
valu
significantli
better
detect
signific
fibrosi
auc
p
auc
p
respect
tabl
moreov
lsm
cutoff
signific
fibrosi
kpa
close
propos
studi
liver
biopsi
gener
accept
reliabl
method
evalu
degre
liver
fibrosi
howev
invas
procedur
carri
often
follow
diseas
progress
therefor
field
noninvas
approach
liver
stage
recent
evolv
noninvas
marker
serum
marker
liver
stiff
measur
lsm
signific
indic
liver
stiff
liver
fibrosi
transient
elastographi
may
use
aid
andor
replac
liver
biopsi
stage
liver
fibrosi
present
studi
first
one
evalu
diagnost
accuraci
characterist
serum
level
hcv
patient
signific
advanc
fibrosi
princip
find
follow
provid
clinic
relev
diagnost
accuraci
singl
marker
predict
fibrosi
stage
accuraci
level
diagnos
signific
liver
fibrosi
measur
sensit
specif
ppv
npv
significantli
higher
accuraci
gpr
ratio
auc
score
auc
similar
apri
index
auc
ha
auc
could
altern
noninvas
serum
marker
liver
biopsi
assess
liver
fibrosi
studi
clearli
demonstr
level
hcv
patient
increas
progress
liver
fibrosi
stage
compli
previou
studi
show
close
associ
level
diseas
progress
stage
liver
fibrosi
patient
nonalcohol
steatohepat
andor
alcohol
hepat
chronic
viral
hepat
c
result
studi
demonstr
among
ten
variabl
includ
level
platelet
count
albumin
ast
alt
ggt
total
bilirubin
inr
ha
direct
fibrosi
marker
signific
serum
marker
associ
sever
liver
fibrosi
although
posit
correl
progress
liver
fibrosi
stage
rho
p
patient
hcv
result
vivo
ex
vivo
vitro
studi
suggest
exert
hepatoprotect
modulatori
effect
chronic
inflammatori
event
take
account
fact
protein
regul
conserv
mice
human
one
like
explan
appar
contradictori
result
might
express
strong
evid
emerg
studi
perea
et
al
suggest
liver
may
import
sourc
circul
inde
demonstr
hepat
gene
express
plasma
level
show
posit
correl
patient
alcohol
hepat
alcohol
cirrhosi
independ
etiolog
common
hallmark
chronic
liver
diseas
chronic
inflamm
show
correl
progress
fibrosi
injur
liver
chemotact
stimuli
trigger
rapid
recruit
immun
cell
includ
macrophag
neutrophil
infiltr
immun
cell
produc
numer
proinflammatori
cytokin
growth
factor
trigger
activ
myofibroblast
main
effector
cell
tissu
remodel
accordingli
reason
believ
increas
circul
level
like
trigger
ongo
product
proinflammatori
cytokin
necroinflammatori
injuri
includ
known
potent
induc
releas
phenomenon
may
also
reflect
signific
correl
serum
level
hepat
necroinflammatori
activ
rho
p
patient
hcv
earli
stage
fibrosi
reduc
product
may
effici
advanc
fibrosi
stage
inflamm
contrari
liver
injuri
model
defici
affect
necrosi
howev
associ
augment
fibrosi
therefor
research
need
clarifi
molecular
mechan
hepat
product
hcv
patient
differ
necroinflammatori
activ
grade
studi
show
sever
risk
score
apri
index
score
gpr
ratio
appear
good
surrog
marker
predict
fibrosi
stage
auc
report
fibrosi
marker
apri
index
score
gpr
ratio
ha
lsm
valu
increas
liver
fibrosi
stage
progress
auc
increas
accordingli
well
diagnost
perform
significantli
better
gpr
ratio
detect
auc
worth
note
show
better
diagnost
accuraci
score
overlap
confid
interv
therefor
significantli
differ
sever
studi
evalu
diagnost
perform
score
apri
index
noninvas
algorithm
detect
signific
andor
advanc
fibrosi
obtain
similar
result
us
except
wai
et
al
found
mean
apri
auc
signific
fibrosi
apri
test
show
auc
detect
signific
fibrosi
rang
similar
diagnost
perform
light
observ
result
possibl
use
earli
marker
predict
fibrosi
stage
promis
preclin
clinic
studi
need
elucid
precis
role
fibrosi
three
main
strength
studi
firstli
sampl
size
n
larg
enough
includ
welldetermin
baselin
clinic
characterist
although
number
patient
enrol
might
seem
rel
small
adequ
repres
sampl
size
estim
provid
specif
power
secondli
studi
exclud
patient
fatti
liver
diseas
may
affect
lsm
valu
thirdli
major
strength
studi
comparison
novel
elastographi
techniqu
fulfil
number
requir
ideal
noninvas
marker
fibrosi
howev
limit
lack
standard
cutoff
diagnos
fibrosi
stage
reli
singl
determin
take
account
variat
may
occur
time
howev
seem
major
limit
fibrosi
marker
measur
studi
final
liver
biopsi
prone
sampl
error
scope
evalu
degre
liver
fibrosi
lead
bia
despit
fact
studi
detect
signific
fibrosi
similar
accuraci
indirect
biomark
apri
still
clinic
relev
reflect
fibrosisrel
inflamm
liver
function
apri
calcul
ast
alt
valu
recent
progress
antivir
treatment
normal
ast
alt
valu
mani
patient
even
though
still
fibrot
liver
context
may
clinic
relev
term
gener
clinic
practic
relat
monitor
patient
whose
treatment
defer
reconsid
indic
treatment
discuss
new
therapi
emerg
conclus
assess
detect
clinic
signific
advanc
fibrosi
patient
chronic
hepat
c
prove
use
singl
diagnost
marker
new
studi
manuscript
articl
prepar
base
find
show
signific
correl
valu
degre
liver
fibrosi
combin
ha
valu
defin
new
index
